#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2644	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2782	232.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	2055	2055	T	298	T	275	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2644	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2782	232.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1789	1789	C	327	C,A	314,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4650	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4196	275.3	0	.	n	.	0	A9G	SNP	9	9	A	656	656	G	352	G	338	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4650	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4196	275.3	0	.	n	.	0	T695C	SNP	695	695	T	1342	1342	C	396	C,T,A,G	372,1,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4650	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4196	275.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2618	2618	C	322	C,T	308,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4650	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4196	275.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3244	3244	T	327	T,C	306,4	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4650	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4196	275.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2692	2692	A	324	A,T,C	315,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	194	folP	855	855	99.77	folP.l15.c4.ctg.1	1955	24.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1279	1281	AGC	39;39;38	A,G;G;C	37,1;38;37	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	372	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	4119	22.5	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1406	1408	ATA	38;38;37	A;T;A	37;37;36	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	372	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	4119	22.5	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1427	1429	ATA	37;37;38	A;T;A	35;36;35	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	372	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	4119	22.5	1	SNP	p	S91F	0	.	.	271	273	TCC	950	952	TCC	20;20;21	T;C;C	20;20;20	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	372	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	4119	22.5	1	SNP	p	D95G	0	.	.	283	285	GAC	962	964	GAC	20;20;20	G;A;C	19;19;19	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	372	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	4119	22.5	1	SNP	p	D95N	0	.	.	283	285	GAC	962	964	GAC	20;20;20	G;A;C	19;19;19	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	190	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1725	27.1	0	.	p	.	0	P191fs	FSHIFT	571	571	C	1162	1162	C	38	C	37	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	190	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1725	27.1	1	SNP	p	G45D	0	.	.	133	135	GGC	723	725	GGC	52;52;52	G;G;C	45;46;45	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	122	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1553	19.2	0	.	n	.	0	.206T	INS	206	206	T	888	888	T	35	T	34	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1847	1849	GCC	39;39;37	G;C;C	38;37;36	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1889	1891	GCA	37;37;37	G;C;A	35;35;34	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	1	SNP	p	D86N	0	.	.	256	258	GAC	842	844	GAC	40;40;41	G;A;C,A	34;33;35,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	1	SNP	p	S87R	0	.	.	259	261	AGT	845	847	AGT	39;39;40	A;G;T,G	33;33;36,2	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	1	SNP	p	S87I	0	.	.	259	261	AGT	845	847	AGT	39;39;40	A;G;T,G	33;33;36,2	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	1	SNP	p	S87W	0	.	.	259	261	AGT	845	847	AGT	39;39;40	A;G;T,G	33;33;36,2	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	448	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3446	32.0	1	SNP	p	S88P	0	.	.	262	264	TCC	848	850	TCC	40;39;40	T;C;C	36;36;38	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	390	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3280	29.2	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1856	1858	GGT	27;27;27	G;G;T	27;25;27	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1600	1602	GCA	49;49;49	G,C;C;A	46,1;46;46	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1603	1605	ATC	49;49;49	A;T;C	44;48;48	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1615	1617	GTG	50;50;50	G;T;G	47;46;47	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1615	1617	GTG	50;50;50	G;T;G	47;46;47	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2119	2121	ACC	41;41;41	A,G;C,A;C	34,1;36,2;39	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2173	2175	GCG	35;38;38	G;C,G,A;G	33;30,1,1;33	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2173	2175	GCG	35;38;38	G;C,G,A;G	33;30,1,1;33	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2296	2298	GGT	36;36;36	G;G;T	36;36;36	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2305	2307	GGC	32;32;32	G;G;C	32;31;31	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	436	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2770	38.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2323	2325	CCG	32;31;30	C;C;G	31;30;30	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	868	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3262	64.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	222	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2386	23.2	0	.	p	.	0	S22G	NONSYN	64	66	AGC	689	691	GGC	32;32;32	G;G;C	29;29;27	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	222	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2386	23.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	871	871	C	25	C	22	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	T18M	NONSYN	52	54	ACG	842	844	ATG	45;46;49	A;T;G	45;46;49	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	I45V	NONSYN	133	135	ATT	923	925	GTT	67;65;65	G;T,A,C;T	65;61,1,1;63	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	N121S	NONSYN	361	363	AAC	1151	1153	AGC	41;41;42	A;G;C	38;38;41	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1154	1156	AAA	42;42;43	A,C;A;A	40,1;40;43	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	1181	1183	TAT	46;47;47	T;A;T	46;46;43	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	N134K	NONSYN	400	402	AAT	1190	1192	AAG	49;50;50	A;A;G	44;47;49	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	V135F	NONSYN	403	405	GTG	1193	1195	TTT	51;51;51	T,A,G,C;T;T,G	48,1,1,1;51;49,2	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1208	1210	AAA	50;50;50	A;A;A	50;49;49	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	Q143E	NONSYN	427	429	CAA	1217	1219	GAA	48;51;51	G;A;A	46;45;46	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1241	1243	GCA	46;47;47	G;C;A,T	44;45;43,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	K207_M208insK	INS	619	619	A	1409	1409	A	53	A,T	51,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	A212S	NONSYN	634	636	GCA	1427	1429	TCA	59;59;60	T,G;C,T;A	55,2;56,1;58	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	314	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	2426	32.3	0	.	p	.	0	Y251fs	FSHIFT	751	751	T	1544	1544	T	41	T,G	39,1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1360	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5361	62.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2240	2242	CAT	77;75;76	C;A;T	71;70;71	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	236	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1548	37.6	1	SNP	p	V57M	1	.	.	169	171	ATG	713	715	ATG	77;75;76	A;T;G	73;73;74	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
